Table 1.
Patient Demographics and Medical Characteristics
| Patient Information | Active cGVHD (n = 59) | No cGVHD Reference Sample (n = 19) |
|---|---|---|
| Mean Age | 59.0 | 50.4 |
| Female Sex, No. (%) | 22 (37.29) | 6 (31.58) |
| Race/Ethnicity, No.(%) | ||
| Caucasian/ White | 57 (96.61) | 18 (94.74) |
| Latina/Latino | 1 (1.70) | 0 (0) |
| Other | 1 (1.70) | 0 (0) |
| No response | 0 (0) | 1 (5.26) |
| Relationship Status, No. (%) | ||
| Married/living with partner | 49 (83.05) | 14 (73.68) |
| Divorced | 3 (5.09) | 3 (15.79) |
| Single | 6 (10.17) | 2 (10.53) |
| Widowed | 1 (1.70) | 0 (0) |
| Education, No. (%) | ||
| Less than 12 years | 1 (1.70) | 0 (0) |
| High School | 14 (23.73) | 5 (26.32) |
| Trade School | 10 (16.95) | 1 (5.26) |
| Some College | 17 (28.81) | 2 (10.53) |
| College Graduate | 13 (22.03) | 8 (42.11) |
| Post-graduate Degree | 4 (6.78) | 2 (10.53) |
| No response | 0 (0) | 1 (5.26) |
| Employment Status, No. (%) | ||
| Full-time | 9 (15.25) | 5 (26.32) |
| Part-time | 12 (20.34) | 2 (10.53) |
| Student | 0 (0) | 1 (5.26) |
| Disabled | 16 (27.12) | 3 (15.79) |
| Homemaker | 1 (1.70) | 0 (0) |
| Retired | 20 (33.90) | 6 (31.58) |
| No response | 1 (1.70) | 2 (10.53) |
| Annual Income, No. (%) | ||
| Less than $10,000 | 1 (1.70) | 0 (0) |
| $10,001–$25,000 | 7 (11.86) | 1 (5.26) |
| $25,001–$40,000 | 7 (11.86) | 6 (31.58) |
| $40,001–$55,000 | 12 (20.34) | 1 (5.26) |
| $55,001–$70,000 | 6 (10.17) | 1 (5.26) |
| $70,001–$85,000 | 7 (11.86) | 2 (10.53) |
| $85,001–$100,000 | 8 (13.56) | 5 (26.32) |
| More than $100,000 | 7 (11.86) | 2 (10.53) |
| No response | 4 (6.78) | 1 (5.26) |
| Time Since HCT (Months) | 61 (11–147) | 42 (9–100) |
| Diagnosis, No. (%) | ||
| ALL | 3 (5.08) | 2 (10.53) |
| AML | 24 (40.68) | 5 (26.32) |
| Aplastic Anemia | 0 (0) | 1 (5.26) |
| CLL | 2 (3.39) | 1 (5.26) |
| CML | 8 (13.56) | 2 (10.53) |
| Hodgkin Lymphoma | 0 (0) | 1 (5.26) |
| MDS | 9 (15.25) | 4 (21.05) |
| Non-Hodgkin Lymphoma | 10 (16.95) | 1 (5.26) |
| Other | 3 (5.08) | 2 (10.53) |
| DRI Score, No. (%) | ||
| Low | 26 (44.07) | 6 (31.58) |
| Intermediate | 25 (42.37) | 9 (47.37) |
| High | 7 (11.86) | 2 (10.53) |
| Very High | 0 (0) | 0 (0) |
| N/A | 1 (1.70) | 2 (10.53) |
| Donor Female, No. (%) | 26 (44.07) | 5 (26.32) |
| Unknown | 4 (6.78) | 1 (5.26) |
| Graft Source | ||
| Bone Marrow | 5 (8.47) | 1 (5.26) |
| Cord Blood | 0 (0) | 4 (21.05) |
| Peripheral Blood | 54 (91.53) | 14 (73.68) |
| Graft Match, No. (%) | ||
| Full Matched Unrelated | 21 (35.59) | 10 (52.63) |
| Mismatched Unrelated | 2 (3.39) | 3 (15.79) |
| Matched Relative | 30 (50.85) | 4 (21.05) |
| Mismatched Relative | 4 (6.78) | 0 (0) |
| Unknown | 2 (3.39) | 2 (10.53) |
| Conditioning Regimen, No. (%) | ||
| Myeloablative | 23 (38.98) | 5 (26.32) |
| Non-Myeloablative | 24 (40.68) | 13 (68.42) |
| TBI | 26 (44.07) | 14 (73.68) |
| Unknown | 3 (5.09) | 2 (10.53) |
| GVHD Prophylaxis | ||
| CNI + methotrexate | 49 (83.05) | 8 (42.10) |
| CNI + other | 4 (6.78) | 6 (31.58) |
| Other / unknown | 4 (10.17) | 5 (26.32) |
| Acute GVHD, No. (%) | 23 (38.98) | 0 (0) |